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AbstrAct
Dual antiplatelet therapy (DAPT) combining aspirin and 
a P2Y12 receptor inhibitor has been consistently shown 
to reduce recurrent major adverse cardiovascular events 
(MACE) in patients with acute coronary syndrome (ACS) 
or undergoing percutaneous coronary intervention (PCI) 
for stable coronary artery disease (CAD) compared 
with aspirin monotherapy, but at the expense of an 
increased risk of major bleeding. Nevertheless, the 
optimal duration of DAPT for secondary prevention of 
CAD remains uncertain, owing to the conflicting results 
of several large randomised trials. Among patients with 
stable CAD undergoing PCI with drug-eluting stents 
(DES), shorter durations of DAPT (3–6 months) were 
shown non-inferior to 12 or 24 months duration with 
respect to MACE, but reduced the rates of major bleeding. 
Contrariwise, prolonged DAPT durations (18–48 months) 
reduced the incidence of myocardial infarction and stent 
thrombosis, but at a cost of an increased risk of major 
bleeding and all-cause mortality. Until more evidence 
becomes available, the choice of optimal DAPT regimen 
and duration for patients with CAD requires a tailored 
approach based on the patient clinical presentation, 
baseline risk profile and management strategy. Future 
studies are however needed to identify patients who may 
derive benefit from shortened or extended DAPT courses 
for secondary prevention of CAD based on their individual 
ischaemic and bleeding risk. Based on limited evidence, 
12 months duration of DAPT is currently recommended 
in patients with ACS irrespective of their management 
strategy, but large ongoing randomised trials are currently 
assessing the efficacy and safety of a short-term DAPT 
strategy (3–6 months) for patients with ACS undergoing 
PCI with newer generation DES. Finally, several ongoing, 
large-scale, randomised trials are challenging the current 
concept of DAPT by investigating P2Y
12 receptor inhibitors 
as single antiplatelet therapy and may potentially shift 
the paradigm of antiplatelet therapy after PCI in the 
near future. This article provides a contemporary state-
of-the-art review of the current evidence on DAPT for 
secondary prevention of patients with CAD and its future 
perspectives.
IntroductIon
Antiplatelet therapy represents the main-
stay of the pharmacological treatment and 
secondary prevention of coronary artery 
disease (CAD). Compared with placebo, anti-
platelet therapy has been shown to reduce 
recurrent major adverse cardiovascular 
events (MACE) among patients with stable 
CAD or acute coronary syndrome (ACS).1 
Dual antiplatelet therapy (DAPT) provides 
more intense platelet inhibition than single 
antiplatelet therapy resulting in incremental 
reductions in the risk of thrombotic events 
after percutaneous coronary intervention 
(PCI) or ACS, but it has been associated 
with an increased risk of major bleeding.2–5 
The choice of optimal DAPT regimen and 
duration for patients with CAD requires a 
tailored approach based on the patient clin-
ical presentation, baseline risk profile and 
management strategy. However, the selec-
tion of patients who might derive benefit 
from shorter or extended DAPT duration 
remains a matter of debate. This article 
provides a contemporary state-of-the-art 
review of the current evidence on DAPT for 
secondary prevention of patients with CAD 
and its future perspectives.
AntIplAtelet Agents
Platelet inhibition plays a central role for 
treatment and prevention of short- and 
long-term atherothrombotic events in 
patients with CAD. Oral antiplatelet agents 
for secondary prevention of patients with 
CAD include the cyclo-oxygenase-1 inhibitor 
aspirin, and the platelet adenosine diphos-
phate P2Y12 receptor inhibitors clopidogrel, 
prasugrel and ticagrelor. Aspirin and clopi-
dogrel have been studied across the whole 
spectrum of CAD, whereas the more recent 
potent P2Y12 platelet receptor inhibitors 
prasugrel and ticagrelor have been evaluated 
in patients with ACS. The main characteris-
tics, mechanisms of action and indications of 
oral antiplatelet agents used for secondary 
prevention of CAD are summarised in table 1. 
Although there are several potential combi-
nations of antiplatelet agents, DAPT refers 
to the therapy combining aspirin and a P2Y12 
receptor inhibitor (clopidogrel, prasugrel or 
ticagrelor). DAPT has been shown to reduce 
recurrent major ischaemic events in patients 
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with ACS or undergoing PCI,1 at the expense of an 
unavoidable increased risk of major bleeding compared 
with single antiplatelet therapy. A personalised approach 
based on the patient clinical presentation (stable CAD or 
ACS), baseline ischaemic and bleeding risk profiles, and 
management strategy (conservative treatment, PCI or 
coronary artery bypass graft (CABG)) is currently advo-
cated.2–5
stAble cAd
Aspirin remains the cornerstone for secondary preven-
tion of patients with stable CAD, irrespective of the 
management strategy. In a large meta-analysis including 
16 secondary prevention trials and 17 000 high-risk 
patients, low-dose aspirin (75–150 mg/day) was associated 
with a 20% relative risk reduction in MACE (cardiovas-
cular (CV) death or non-fatal myocardial infarction (MI)) 
(rate ratio 0.80, 95% CI 0.73 to 0.88), a 31% relative risk 
reduction in MI (RR 0.69, 95% CI 0.60 to 0.80) and a 
22% relative risk reduction in ischaemic stroke (RR 0.78, 
95% CI 0.61 to 0.99), at the expense of an increased risk 
of haemorrhagic stroke (RR 1.67, 95% CI 0.97 to 2.90) 
and major extracranial bleeding (RR 2.69, 95% CI 1.25 
to 5.76).1 Aspirin marginally reduced CV mortality (RR 
0.91, 95% CI 0.82 to 1.00, p=0.06), resulting in a 10% rela-
tive risk reduction in all-cause mortality (RR 0.90, 95% CI 
0.82 to 0.99, p=0.02).1 At variance of the antiplatelet 
effects, the gastrointestinal side effects of aspirin increase 
at higher doses. The optimal risk:benefit ratio appears to 
be achieved with an aspirin dosage of 75–150 mg daily.2 6
The Clopidogrel versus Aspirin in Patients at Risk of Isch-
aemic Events (CAPRIE) trial compared antiplatelet 
therapy with clopidogrel (75 mg daily) versus aspirin 
(325 mg daily) in 19 185 patients with atherosclerotic 
cardiovascular disease (ACVD) (recent ischaemic stroke, 
recent MI or symptomatic peripheral arterial disease 
(PAD)).7 Compared with aspirin, long-term administra-
tion of clopidogrel (median follow-up 2 years) was asso-
ciated with significant risk reductions in the combined 
endpoint of CV death, MI or ischaemic stroke (5.32% 
per year vs 5.83% per year, relative risk reduction 
8.7%, 95% CI 0.3 to 16.5, p=0.04) without significantly 
increased risk of severe intracranial (0.31% vs 0.43%, 
p=0.23) and gastrointestinal bleedings (0.49% vs 0.71%, 
p=0.05).7 Importantly, the superiority of clopidogrel 
over aspirin was mainly driven by a reduction of events in 
the PAD, but not MI, subgroup.7 Although potent P2Y12 
receptor inhibitors have shown superior efficacy than 
clopidogrel in patients with ACS, there is currently little 
evidence to support the use of prasugrel and ticagrelor 
in patients with stable CAD.
According to current guidelines, long-term low-dose 
aspirin is recommended in all patients with stable CAD 
(class I).2 6 Clopidogrel (75 mg daily) is indicated as an 
alternative in case of aspirin intolerance (class I).2 Alter-
natively, aspirin desensitisation may also be considered in 
patients with a compelling need for aspirin therapy.
conservative treatment
Data supporting the benefits of long-term DAPT in 
unselected patients with stable CAD are limited. The 
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabi-
lisation, Management and Avoidance (CHARISMA) trial 
randomly assigned 15 603 patients with documented 
ACVD (CAD, cerebrovascular disease or PAD) or multiple 
atherothrombotic risk factors to receive clopidogrel 
(75 mg daily) versus placebo in addition to low-dose 
aspirin (75–162 mg daily).8 Overall, rates of the primary 
composite endpoint (CV death, MI or stroke) were 
similar in the clopidogrel plus aspirin and aspirin alone 
groups after a median follow-up of 28 months (6.8% vs 
7.3%, 95% CI 0.83 to 1.05, p=0.22), despite a marginally 
increased risk of severe bleeding among patients treated 
with DAPT (1.7% vs 1.3%, RR 1.25, 95% CI 0.97 to 1.61, 
p=0.09).8 In the subgroup of patients with multiple risk 
factors, the rates of the primary endpoint (6.6% vs 5.5%, 
RR 1.2, 95% CI 0.91 to 1.59, p=0.20) and CV death were 
higher in clopidogrel-treated patients  (3.9% vs 2.2%, 
p=0.01). In the prespecified subgroup of patients with 
clinically evident ACVD (n=12 153), there was a marginally 
significant reduction in the primary ischaemic endpoint 
in the clopidogrel plus aspirin group (6.9% vs 7.9%, RR 
0.88, 95% CI 0.77 to 0.998, p=0.046), whereas asympto-
matic patients with multiple risk factors only (n=3284) 
assigned to clopidogrel plus aspirin experienced a 20% 
relative risk increase in the rate of primary ischaemic 
events (6.6% vs 5.5%, p=0.20) and a significant increase 
in rates of all-cause (5.4% vs 3.8%, p=0.04) and CV death 
(3.9% vs 2.2%, p=0.01), compared with those assigned 
to aspirin alone.8 In a posthoc subgroup analysis of 9478 
patients with prior MI, ischaemic stroke or PAD, rates 
of the primary composite endpoint (7.3% vs 8.8%, HR 
0.83, 95% CI 0.72 to 0.96, p=0.01) and hospitalisations for 
ischaemia (11.4% vs 13.2%, HR 0.86, 95% CI 0.76 to 0.96, 
p=0.008) were significantly lower in the clopidogrel plus 
aspirin arm than in the aspirin alone arm.9 In patients 
treated with DAPT, there was a significantly increased risk 
of moderate bleeding (2.0% vs 1.3%, HR 1.60, 95% CI 
1.16 to 2.20, p=0.004) with no significant difference in 
rates of severe bleeding (1.7% vs 1.5%, HR 1.12, 95% CI 
0.81 to 1.53, p=0.50).9
Routine DAPT is currently not recommended for 
patients with stable CAD without history of ACS, PCI or 
CABG within 12 months (class III).2 6 Results from the 
CHARISMA trial suggest the potential benefits of DAPT 
with aspirin and clopidogrel beyond aspirin alone in a 
subgroup of patients with stable CAD and at high risk of 
CV events9 (figure 1).
percutaneous coronary intervention
The combination of aspirin and P2Y12 receptor inhibitor 
therapy remains the mainstay of pharmacological treat-
ment for patients undergoing PCI with bare metal stents 
(BMS) or drug-eluting stents (DES). Among patients 
undergoing PCI, DAPT with aspirin and a P2Y12 receptor 
antagonist (ticlopidine) during 4–6 weeks significantly 
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reduced rates of MACE compared with combined 
aspirin and oral anticoagulation (OAC) therapy10–13 or 
aspirin single antiplatelet therapy,12 and decreased major 
bleeding rates compared with combination of aspirin and 
OAC.10–13 However, prolonged DAPT duration increases 
the risk of major bleeding compared with aspirin alone, 
which has been strongly related to an increased risk of 
short14 and long-term mortality.15 The Clopidogrel for the 
Reduction of Events during Observation (CREDO) trial 
randomly assigned 2116 patients scheduled for elective 
PCI or deemed at high likelihood of undergoing PCI to 
receive clopidogrel for up to 1 year (preceded by a 300 mg 
loading dose) or for 1 month (without loading dose), in 
addition to aspirin.16 At 1 year, long-term clopidogrel 
therapy was associated with a 27% relative risk reduc-
tion in the combined ischaemic endpoint (death, MI or 
stroke) (95% CI 3.9% to 44.4%, p=0.02; absolute reduc-
tion 3%) compared with a short clopidogrel regimen, 
at the expense of a marginally increased risk of major 
bleeding (8.8% vs 6.7%, p=0.07).16
While there is general consensus on 1-month DAPT 
duration after BMS implantation,2 3 6 the optimal dura-
tion of DAPT after DES implantation remains a matter of 
debate. Newer generation DES with thinner strut thick-
ness, biocompatible or biodegradable polymer coatings, 
and reduced sirolimus-analogue antiproliferative drug 
doses have been developed to improve arterial healing 
and reduce the risk of late thrombotic adverse events, 
which may potentially mitigate the need for prolonged 
intense platelet inhibition after DES implantation.17 The 
conflicting evidence concerning optimal DAPT dura-
tion after DES implantation is reflected in the contra-
dictory results of 12 randomised controlled trials (RCT) 
performed to date to address this challenging and 
unsolved clinical issue.18–29 The inconsistent results may 
in part be explained by important differences in study 
designs, patient risk profiles, DAPT strategies, DES types 
implanted and study primary endpoints. Most of the 
trials have been characterised by slow enrolment, inclu-
sion of low-risk patients and limited statistical power 
due to sample size estimates based on large event rates 
reductions or non-inferiority margins, coupled with 
lower than anticipated observed event rates. In addition, 
several study designs combined both efficacy and safety 
outcomes into a single primary endpoint, thus confusing 
the relative risks and benefits of individual ischaemic and 
bleeding outcomes.
Most of contemporary studies have compared either 
shorter (3–6 months) or longer (18–48 months) courses 
of DAPT versus 12-month DAPT duration, which has 
traditionally been considered as the recommended 
DAPT duration for most patients after DES implan-
tation. Seven RCTs have consistently reported similar 
ischaemic outcomes but significantly reduced major 
bleeding rates with shorter 3- or 6-month compared 
with longer (≥12 months) DAPT durations after DES 
implantation18–24 (table 2). Conversely, with the excep-
tion of the DAPT study,25 four RCTs have consistently 
failed to demonstrate a reduction in ischaemic events 
with DAPT prolongation beyond 12 months (up to 
Figure 1 P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. BMS, bare 
metal stent; CABG, coronary artery bypass graft surgery; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting 
stent; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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48 months), as compared with 12-month DAPT26–29 
(table 3).
The Dual Antiplatelet Therapy (DAPT) study randomly 
assigned 9961 patients who underwent PCI with DES to 
continue thienopyridine therapy or to receive placebo 
for 18 months in addition to aspirin, after 12 months of 
DAPT combining aspirin and a thienopyridine (clopi-
dogrel or prasugrel). Prolonged DAPT (30 months) 
after DES significantly reduced rates of stent throm-
bosis (ST) (0.4% vs 1.4%, HR 0.29, 95% CI 0.17 to 
0.48, p<0.001), MACE (4.3% vs 5.9%, HR 0.71, 95% CI 
0.59 to 0.85, p<0.001) and MI (2.1% vs 4.1%, HR 0.47, 
p<0.001), compared with 12-month DAPT duration.25 
Continued thienopyridine therapy beyond 12 months 
was associated with marginally increased rates of all-cause 
mortality (2.0% vs 1.5%, HR 1.36, 95% CI 1.00 to 1.85, 
p=0.05) and a significantly increased risk of moderate or 
severe bleeding (2.5% vs 1.6%, p=0.001) compared with 
12-month DAPT.25 Finally, there was an increased risk of 
ST and MI in both treatment groups during the 3 months 
Table 2 Overview of major randomised controlled trials comparing short-term (3–6 months) versus long-term (≥12 months) 
DAPT duration after drug-eluting stent implantation
Trial
Patients 
(N)
Clinical 
presentation
DAPT 
duration Ischaemic endpoints Bleeding endpoints
EXCELLENT
Gwon et al18
1443 SCAD 49%
ACS 51%
6 vs 
12 months
TVF (CV death, MI or ischaemia-driven TVR): 4.8% vs 4.3%, 
HR, 95% CI 0.70 to 1.86, p=0.001; MACE (death, MI, stroke 
or any revascularisation): 8.0% vs 8.5%, HR 0.94, 95% CI 
0.65 to 1.35, p=0.72; CV death: 0.3% vs 0.4%, HR 0.67, 
95% CI 0.11 to 3.99, p=0.66; MI: 1.8% vs 1.0%, HR 1.86, 
95% CI 0.74 to 4.67, p=0.19; ST: 0.9% vs 0.1%, HR 6.02, 
95% CI 0.72 to 49.96, p=0.10
TIMI major bleeding: 
0.3% vs 0.6%, HR 0.50, 
95% CI 0.09 to 2.73, 
p=0.42
RESET
Kim et al19
2117 SCAD 46%
ACS 54%
3 vs 
12 months
MACE (all-cause death, MI or ST): 0.8% vs 1.3%, p=0.48; CV 
death: 0.2% vs 0.4%, p=0.41; MI: 0.2% vs 0.4%, p=0.41; 
definite/probable ST: 0.2% vs 0.3%, p=0.65
TIMI major bleeding 0.2% 
vs 0.6%, p=0.16
PRODIGY
Valgimigli et al20
2013 SCAD 26%
ACS 74%
6 vs 
24 months
MACE (all-cause death, MI or stroke): 10.0% vs 10.1%, HR 
0.98, 95% CI 0.74 to 1.29, p=0.91; CV death: 3.8% vs 3.7%, 
HR 1.03, 95% CI 0.66 to 1.61, p=0.89; MI: 4.2% vs 4.0%, 
HR 1.06, 95% CI 0.69 to 1.63, p=0.80; definite/probable ST: 
1.5% vs 1.3%, HR 1.15, 95% CI 0.55 to 2.41, p=0.70
BARC type 2, 3, 5 major 
bleeding: 3.5% vs 7.4%, 
HR 0.46, 95% CI 0.31 to 
0.69, p=0.00018; TIMI 
major bleeding: 0.6% vs 
1.6%, HR 0.38, 95% CI 
0.15 to 0.97, p=0.041
OPTIMIZE
Feres et al21
3119 SCAD 68%
ACS 32%
3 vs 
12 months
All-cause death: 2.8% vs 2.9%, HR 0.95, 95% CI 0.63 to 
1.45, p=0.82; CV death: 1.9% vs 2.1%, HR 0.90, 95% CI 
0.55 to 1.49, p=0.69; MI: 3.2% vs 2.7%, HR 1.17, 95% CI 
0.77 to 1.76, p=0.47; MACE (all-cause death, MI, emergent 
CABG or TLR): 8.3% vs 7.4%, HR 1.12, 95% CI 0.87 to 1.45, 
p=0.36; definite/probable ST: 0.8% vs. 0.8%, HR 1.08, 
95% CI 0.49 to 2.36, p=0.86
Major REPLACE-2 and 
severe or life-threatening 
GUSTO bleedings: 0.6% 
vs 0.9%, HR 0.71, 95% CI 
0.32 to 1.60, p=0.41
SECURITY
Colombo et al22
1399 SCAD 62%
ACS 38%
6 vs 
12 months
CV death: 0.7% vs 0.4%, p=0.435; MI: 2.3% vs 2.1%, 
p=0.747; definite/probable ST: 0.3% vs 0.4%, p=0.694
BARC type 3 or 5 at 
12 months: 0.6% vs 
1.1%, p=0.283
ITALIC
Gilard et al23
1894 SCAD 56%
ACS 44%
6 vs 
24 months
All-cause death: 0.9% vs 0.8%, HR 1.14, 95% CI 0.41 to 
3.15, p=0.80; CV death: 0.5% vs 0.3%, HR 1.67, 95% CI 
0.39 to 6.97; p=0.48; MI: 0.7% vs 0.4%, HR 1.50, 95% CI 
0.42 to 5.32, p=0.53; TVR: 0.5% vs 0.2%, HR 2.49, 95% CI 
0.48 to 12.88, p=0.27; ST: 0.3% vs 0%
TIMI major bleeding: 0 
vs 0.3%
ISAR-SAFE
Schulz-
Schüpke et al24
4000 SCAD 60%
ACS 40%
6 vs 
12 months
MACE (all-cause death, MI, definite/probable
ST or stroke): 1.3% vs 1.5%, HR 0.87, 95% CI 0.51 to 1.47, 
p=0.59; all-cause death: 0.4% vs 0.6%, HR 0.66, 95% CI 
0.27 to 1.63, p=0.37; MI: 0.7% vs 0.7%, HR 0.93, 95% CI 
0.44 to 1.97, p=0.85; definite/probable ST: 0.3% vs 0.2%, 
HR 1.25, 95% CI 0.33 to 4.65, p=0.74
TIMI major bleeding: 
0.2% vs 0.3%, HR 0.80, 
95% CI 0.21 to 2.98, 
p=0.74
ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium; CABG, coronary artery bypass graft surgery; CV, 
cardiovascular; DAPT, dual antiplatelet therapy; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded 
Coronary Arteries; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiovascular events; MI, myocardial 
infarction; REPLACE, Randomised Evaluation of PCI Linking Angiomax to Reduced Clinical Events; SCAD, stable coronary artery disease; 
ST, stent thrombosis; TIMI, thrombolysis in myocardial infarction; TLR, target lesion revascularisation; TVF, target vessel failure; TVR, target 
vessel revascularisation.
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period following discontinuation of thienopyridine treat-
ment.25 In a posthoc analysis, extended DAPT dura-
tion was associated with significantly increased non-CV 
(0.9% vs 0.5%, p=0.01) but not CV death (1.0% vs 1.0%, 
p=0.97) rates throughout the randomised period.30 The 
rates of fatal bleeding (0.2% vs 0.1%, p=0.81) and death 
related to any prior bleeding (0.3% vs 0.2%, p=0.36) were 
similar between both treatment arms.30 Cancer-related 
deaths were more frequent in patients with extended 
DAPT treatment (0.6% vs 0.3%, p=0.02) and were rarely 
related to bleeding.30 However, rates of cancer occurring 
over the randomised period (2.0% vs 1.6%, p=0.12) or 
after exclusion of patients with cancer diagnosed before 
enrolment (0.4% vs 0.3%, p=0.16) were similar between 
both treatment groups.30 Overall, findings of the DAPT 
study suggest that continuation of DAPT beyond 1 year 
after DES implantation might be considered in selected 
patients at low ischaemic and bleeding risks to reduce the 
rates of ST and MI, at the expense of an increased risk of 
bleeding.
The evidence derived from RCTs addressing different 
DAPT strategies after newer generation DES implan-
tation has been recently combined in several large 
meta-analyses.31–36 Shorter (3–6 months) DAPT courses 
have been associated with similar rates of MACE,34 36 
all-cause death,31–34 36 CV death,31–33 36 MI,31–34 36 ST,31–34 36 
or repeat revascularisation,32 33 36 but with reduced rates 
of major bleeding31–34 36 compared with 12-month DAPT. 
Conversely, extended (18–48 months) DAPT durations 
have been associated with similar rates of MACE,34 
all-cause death,32–34 CV death,31–33 and repeat revasculari-
sation,32 significantly reduced rates of MI31–34 and ST,31–34 
and increased rates of major bleeding31–34 compared 
with shorter (6–12 months) DAPT durations. Although 
the DAPT study25 and two subsequent meta-analyses31–33 
showed that extended DAPT duration beyond 1 year after 
DES may reduce the risk of MI and ST, it has been asso-
ciated with increased mortality due to increased risk of 
non-CV mortality not offset by a reduction in CV mortality. 
However, a recent large meta-analysis including 69 644 
patients undergoing stent implantation did not demon-
strate an association between extended DAPT duration 
and all-cause, CV or non-CV mortality compared with 
aspirin alone or short DAPT duration (≤6 months).35
A personalised approach considering the balance 
between the ischaemic benefit and the bleeding risk 
Table 3 Overview of major randomised controlled trials comparing extended versus standard (12 months) dual antiplatelet 
therapy duration after drug-eluting stent implantation
Trial
Patients 
(N)
Clinical 
presentation
DAPT 
duration Ischaemic endpoints
Bleeding 
endpoints
REAL-LATE/
ZEST-LATE
Park et al26
2701 SCAD 38%
ACS 62%
36 vs 
12 months
MACE (CV death, MI): 1.8% vs 1.2%, HR 1.65, 95% CI 0.80 to 
3.36, p=0.17; all-cause death: 1.6% vs 1.4%, HR 1.52, 95% CI 
0.75 to 3.50, p=0.24; MI: 0.8% vs 0.7%, HR 1.41, 95% CI 
0.54 to 3.71, p=0.49; definite ST: 0.4% vs. 0.4%, HR 1.23, 
95% CI 0.33 to 4.58, p=0.76
TIMI major bleeding: 
0.2% vs 0.1%, HR 2.96, 
95% CI 0.31 to 28.46, 
p=0.35
ARCTIC-
Interruption
Collet et al28
1259 STEMI 0% 18–30 vs 
12 months
MACE (death, MI, ST, stroke or urgent revascularisation): 4.0% 
vs 4.0%, HR 1.17, 95% CI 0.68 to 2.03, p=0.58; all-cause 
death: 1.0% vs 1.0%, HR 1.32, 95% CI 0.49 to 3.55, p=0.58; 
MI: 1.0% vs 1.0%, HR 1.04, 95% CI 0.41 to 2.62, p=0.94; ST or 
any urgent revascularisation: 1.0% vs 2.0%, HR 1.30, 95% CI 
0.51 to 3.30, p=0.58
STEEPLE major 
bleeding: 1.0% 
vs <0.5%, HR
0.15, 95% CI 0.02 to 
1.20, p=0.07
DES LATE
Lee et al27
5045 SCAD 39%
ACS 61%
36 vs 
12 months
MACE (cardiac death, MI or stroke): 2.6% vs 2.4%, HR 0.94, 
95% CI 0.66 to 1.35, p=0.75; all-cause death: 2.0% vs 1.4%, 
HR 0.71, 95% CI 0.45 to 1.10, p=0.12; MI 0.8% vs 1.2%, HR 
1.43, 95% CI 0.80 to 2.58, p=0.23; definite ST: 0.3% vs 0.5%, 
HR 1.59, 95% CI 0.61 to 4.09, p=0.34
TIMI major bleeding: 
1.4% vs 1.1%, HR 0.71, 
95% CI 0.42 to 1.20, 
p=0.20
DAPT
Mauri et al30
9961 SCAD 57%
ACS 43%
30 vs 
12 months
MACCE: 4.3% vs 5.9%, HR 0.71, 95% CI 0.59 to 0.85, p<0.001; 
MI: 2.1% vs 4.1%, HR 0.47, p<0.001; ST: 0.4% vs 1.4%, HR 
0.29, 95% CI 0.17 to 0.48, p<0.001
GUSTO moderate or 
severe bleeding: 2.5% 
vs 1.6%, p=0.001; 
BARC type 2, 3 or 5: 
5.6% vs 2.9%, p<0.001
OPTIDUAL
Helft et al29
1385 SCAD 64%
ACS 36%
48 vs 
12 months
All-cause death: 2.3% vs 3.5%, HR 0.65, 95% CI 0.34 to 1.22, 
p=0.18; MI: 1.6% vs 2.3%, HR 0.67, 95% CI 0.31 to 1.44, 
p=0.31; definite/probable ST: 0.4% vs 0.1%, HR 2.97, 95% CI 
0.31 to 28.53, p=0.35
ISTH major bleeding: 
2.0% vs 2.0%, HR 0.98, 
95% CI 0.47 to 2.05, 
p=0.95
ACS, acute coronary syndrome; CV, cardiovascular; DAPT, dual antiplatelet therapy; GUSTO, Global Utilization of Streptokinase and Tissue 
Plasminogen Activator for Occluded Arteries; ISTH, International Society on Thrombosis and Haemostasis; MACCE, major adverse cardiac 
and cerebrovascular events; MACE, major adverse cardiovascular events; MI, myocardial infarction; SCAD, stable coronary artery disease; 
ST, stent thrombosis; STEEPLE, Safety and Efficacy of Enoxaparin in PCI Patients, an International Randomised Evaluation; STEMI, ST-
elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.
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according to the patient’s clinical profile is currently 
advocated. For most of patients with stable CAD receiving 
contemporary DES, a short-term DAPT strategy (≤6 
months) seems a reasonable approach, and may be 
considered the default therapy in the absence of an 
increased ischaemic risk. The clinical decision to extend 
DAPT duration beyond 1 year (18–48 months) after stent 
implantation requires a personalised evaluation to weigh 
up ischaemic benefits (lower risk of MI and ST) and risks 
(increased risk of major bleeding and non-CV death). 
However, further research is warranted to determine the 
optimal selection of patients who may derive benefit from 
extended DAPT duration after stent implantation.
Lifelong daily low-dose aspirin (75–150 mg) is currently 
recommended for secondary prevention of patients 
undergoing PCI for stable CAD (class I).2 3 6 Clopidogrel 
(75 mg daily) is indicated as an alternative therapy in 
case of aspirin intolerance (class I).2 Current European 
Society of Cardiology and American Heart Association/
American College of Cardiology guidelines recommend 
P2Y12 receptor inhibitor therapy with clopidogrel (75 mg 
daily) for a minimum duration of 1 month after BMS 
(class I) and 6 months after DES implantation (class I) 
for patients with stable CAD undergoing PCI.2 3 6 Due to 
the current lack of evidence in patients with stable CAD, 
the use of potent P2Y12 receptor antagonists, prasugrel or 
ticagrelor, is not recommended in low-risk elective PCI 
(class III), but may be considered in specific high-risk 
elective conditions, such as left main coronary artery PCI 
or patients at high risk of ST or with diabetes (class IIb).2 
Premature discontinuation of P2Y12 receptor therapy after 
3–6 months following DES implantation may be consid-
ered in patients deemed at high bleeding risk or who 
develop significant bleeding (class IIb).3 5 6 In patients at 
high ischaemic risk after BMS or DES implantation who 
have tolerated DAPT without bleeding and who are not 
at high bleeding risk, continuation of DAPT with clopido-
grel for longer than 1 month in patients treated with BMS 
or longer than 6 months in patients treated with DES may 
be reasonable (class IIb)3 6 (figure 1).
The concept of DAPT will be challenged during the 
next years by several ongoing RCTs that will explore 
novel strategies using P2Y12 receptor inhibitors, clopido-
grel (STOPDAPT-2 (NCT02619760), SMART-CHOICE 
(NCT02079194)) or ticagrelor (GLOBAL LEADERS 
(NCT01813435), TWILIGHT (NCT02270242)), as 
single antiplatelet therapy after a short-term (1 or 3 
months) DAPT duration after newer generation DES. 
GLOBAL LEADERS, the largest ongoing trial to date 
(16 001 patients enrolled), is a multicentre, open-
label, randomised study investigating the superiority of 
a 23-month ticagrelor monotherapy (after a 1-month 
DAPT course combining aspirin and ticagrelor) over a 
conventional 12-month DAPT duration consisting of 
aspirin and clopidogrel (stable CAD) or ticagrelor (ACS) 
followed by an additional 12-month course of aspirin 
monotherapy with respect to the composite endpoint of 
all-cause mortality or non-fatal MI at 2 years in all-comers 
patients undergoing PCI with the uniform use of a 
newer generation DES. Similarly, TWILIGHT is a large-
scale randomised, double-blind, placebo-controlled trial 
that will assess the efficacy and safety of ticagrelor mono-
therapy (after a 3-month DAPT course combining aspirin 
and ticagrelor) compared with standard 12-month 
DAPT with aspirin and ticagrelor in up to 9000 high-risk 
patients with stable CAD or ACS undergoing PCI with 
DES. The primary hypothesis of the trial is that ticagrelor 
monotherapy will be superior to DAPT with respect to 
rates of major bleeding, while maintaining non-infe-
riority for the risk of ischaemic events. These trials will 
provide novel insights with respect to the potential role 
of ticagrelor monotherapy as an alternative for long-
term platelet inhibition in a broad population of patients 
undergoing PCI with DES.
Additionally, large all-comers trials are currently eval-
uating the safety and efficacy of an abbreviated 1-month 
DAPT duration compared with standard DAPT dura-
tion (6–12 months) in high bleeding risk patients 
undergoing PCI with newer generation DES (SENIOR 
(NCT02099617), MASTER DAPT (NCT03023020)). 
The highly anticipated results of these studies focused 
on patients who have been traditionally excluded 
from randomised trials on DAPT may provide robust 
randomised evidence to support a short DAPT regimen 
for high bleeding risk patients treated with newer gener-
ation DES in contemporary practice.
cAbg surgery
Antiplatelet therapy with aspirin, preferably when initi-
ated within 24 hours after CABG, has been shown to 
significantly improve early postoperative saphenous vein 
graft patency and reduce major adverse ischaemic events 
in patients undergoing surgical revascularisation.37–39 
While aspirin administration remains a class I indica-
tion, the benefits of combined aspirin and clopidogrel 
therapy after CABG remain controversial.6 In a large 
meta-analysis including 25 728 patients after CABG, early 
saphenous vein graft occlusion (RR 0.59, 95% CI 0.43 to 
0.82, p=0.02) and mortality rates (0.8% vs 1.9%, RR 0.38, 
95% CI 0.26 to 0.57, p<0.0001) were significantly reduced 
among patients receiving aspirin and clopidogrel 
compared with those treated with aspirin alone, whereas 
rates of perioperative angina or MI were similar between 
the two treatment groups (RR 0.60, 95% CI 0.31 to 1.14, 
p=0.12).40 However, patients treated with DAPT showed 
a marginally increased risk of major bleeding, compared 
with those treated with aspirin alone (RR 1.17, 95% CI 
1.00 to 1.37, p=0.05).40 In a pooled subgroup analysis of 
patients undergoing off-pump CABG, combined aspirin 
and clopidogrel therapy significantly reduced periop-
erative MI and saphenous vein graft occlusion rates by 
68% and 55%, respectively.40 In another meta-analysis, 
antiplatelet monotherapy was associated with increased 
rates of early graft occlusion compared with DAPT (7.7% 
vs 5.0%, OR 1.59, 95% CI 1.16 to 2.17, p=0.005).41 These 
findings were mainly driven by significantly increased 
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vein graft occlusion rates in patients treated with single 
antiplatelet therapy (10.8% vs 6.6%, OR 1.70, 95% CI 
1.20 to 2.40, p=0.003), whereas no beneficial effect 
was demonstrated on arterial graft occlusion rates in 
the DAPT group (2.8% vs 2.7%, OR 1.17, 95% CI 0.54 
to 2.56, p=0.84).41 These data might suggest the poten-
tial benefits of DAPT after CABG on vein graft, but not 
arterial graft, patency, at the expense of a marginally 
increased risk of bleeding events (6.3% vs 5.8%, OR 0.98, 
p=0.85).41 A prospective observational study compared 
short- (30 days) versus long-term (mean duration 34 
months) administration of clopidogrel in addition to 
aspirin among 591 consecutive patients undergoing 
isolated off-pump CABG.42 After a mean follow-up of 38 
months, postoperative clopidogrel administration was 
independently associated with reduced MACE (sudden 
cardiac death, MI or coronary reintervention) (OR 
0.20, 95% CI 0.10 to 0.45) and symptom recurrence (OR 
0.30, 95% CI 0.15 to 0.99) rates (p<0.0001 for both).42 
However, there was no significant difference in the inci-
dence of individual ischaemic endpoints (all-cause death, 
sudden cardiac death, MI, congestive heart failure, coro-
nary reintervention or angina) between short- and long-
term clopidogrel administration after multivariate anal-
ysis.42 In the prevention of Coronary arteRY bypaSS occlusion 
After off-pump procedures (CRYSSA) single-centre RCT 
including 300 patients who underwent off-pump CABG, 
combined aspirin and clopidogrel therapy was shown to 
significantly reduce vein graft (7.4% vs 13.1%, p=0.04) 
but not arterial graft occlusion rates (4.9% vs 4.9%) and 
major adverse ischaemic events (death, MI, PCI or stroke) 
(4.7% vs 9.3%, p=0.1), compared with aspirin alone.43 
The rates of minor or major bleeding  events (3.3% vs 
2.6%) were similar between the two treatment arms.
For patients treated with DAPT after PCI who subse-
quently undergo CABG, P2Y12 receptor antagonist 
therapy should be resumed postoperatively to complete 
the recommended DAPT duration (class I).6 In patients 
with stable CAD undergoing CABG, DAPT with clopido-
grel (initiated early in the postoperative period) for 12 
months may be considered to improve vein graft patency 
(class IIb)6 (figure 1). Due to the lack of clinical evidence 
in patients with stable CAD, the use of potent P2Y12 
receptor inhibitors (prasugrel or ticagrelor) is currently 
not recommended. Nevertheless, the efficacy and safety 
of an intensified platelet inhibition using ticagrelor after 
CABG are currently investigated in the Ticagrelor in CABG 
(TiCAB) trial (NCT01755520), an ongoing, multicentre, 
double-blind, double-dummy, randomised trial that 
will compare ticagrelor with aspirin for the prevention 
of MACE within 12 months after CABG. The study will 
randomise 3850 patients undergoing CABG in a 1:1 
fashion to either ticagrelor 90 mg twice daily or aspirin 
100 mg once daily. Of note, the study medication will be 
started within 24 hours after surgery and maintained for 
12 months. The primary endpoint will be a composite of 
CV death, MI, stroke and repeat revascularisation at 12 
months after CABG.
Acute coronAry syndrome
Antiplatelet therapy with aspirin remains the corner-
stone of pharmacological therapy for patients with ACS, 
irrespective of the clinical setting (non-ST-elevation 
ACS (NSTE-ACS), or ST-elevation myocardial infarc-
tion (STEMI)) and the patient management strategy 
(conservative treatment, PCI or CABG).5 6 In a meta-anal-
ysis of 16 secondary prevention trials comparing long-
term aspirin versus control therapy in 17 000 high-risk 
patients, aspirin significantly reduced MACE by 20% 
(absolute benefit 1%/year), non-fatal stroke by 19% and 
CV mortality by 9%.1 However, there is ongoing debate 
regarding the optimal maintenance dose of aspirin for 
secondary prevention of CV events in patients with ACS. 
In the Clopidogrel and Aspirin Optimal Dose Usage to Reduce 
Recurrent Events-Seventh Organization to Assess Strategies in 
Ischemic Syndromes (CURRENT-OASIS 7) trial including 
25 086 patients with ACS, no significant difference was 
observed between high-dose (300–325 mg daily) and 
low-dose (75–100 mg daily) aspirin with regard to the 
composite endpoint of CV death, MI or stroke at 30 days 
(4.2% vs 4.4%, HR 0.97, 95% CI 0.86 to 1.09, p=0.61), 
irrespective of the management strategy (conservative 
treatment or PCI).44 45 Low-dose aspirin was associated 
with significant lower rates of major gastrointestinal 
bleeding (0.2% vs 0.4%, p=0.04), whereas high-dose 
aspirin showed no reduction in rates of the primary 
endpoint (4.1% vs 4.2%, HR 0.98, 95% CI 0.84 to 1.13, 
p=0.76) or major bleeding (1.5% vs 1.3%, HR 1.18, 
95% CI 0.92 to 1.53, p=0.20) in the subgroup of patients 
undergoing PCI.44 45 Furthermore, a subanalysis of the 
Platelet Inhibition and Patient Outcomes (PLATO) trial has 
recently suggested a reduced efficacy of ticagrelor versus 
clopidogrel in ACS patients  treated with high aspirin 
doses, whereas ticagrelor appeared to be more effective 
than clopidogrel in decreasing CV events in patients 
on low-dose aspirin.46 Although the exact mechanism 
underlying the potential interaction between ticagrelor 
and higher aspirin doses remains unclear, a proposed 
hypothesis is linked to the level of P2Y12 inhibition and 
the potential prothrombotic effects of high-dose aspirin 
through the suppression of prostacyclin. Overall, data 
regarding the use of aspirin for secondary prevention of 
CV events in patients with ACS demonstrate a general 
lack of benefit of high maintenance doses of aspirin 
owing to the absence of a dose–response relationship 
between increasing aspirin dose and improved efficacy, 
and a higher incidence of gastrointestinal bleeding with 
increasing aspirin doses. Compared with aspirin mono-
therapy, DAPT provides significant incremental reduc-
tion of CV events in patients with ACS and is considered 
the cornerstone of pharmacological treatment, irrespec-
tive of the management strategy.
conservative treatment
In the Clopidogrel in Unstable Angina to Prevent Recur-
rent Events (CURE) study comparing clopidogrel versus 
placebo in 12 562 patients with ACS, 64% of patients were 
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treated conservatively and did not undergo revascularisa-
tion after randomisation.47 DAPT combining aspirin and 
clopidogrel for 3–12 months was associated with a signif-
icant reduction of the primary composite endpoint (CV 
death, non-fatal MI or stroke) compared with placebo 
(9.3% vs 11.4%, RR 0.80, 95% CI 0.72 to 0.90, p<0.001), at 
the expense of an increased risk of major bleeding in the 
clopidogrel group (3.7% vs 2.7%, RR 1.38, p=0.001).47 
Nevertheless, rates of life-threatening bleeding (2.1% 
vs 1.8%, p=0.13), including fatal bleeding and haemor-
rhagic stroke, were similar between the two treatment 
groups.47
The Targeted Platelet Inhibition to Clarify the Optimal 
Strategy to Medically Manage Acute Coronary Syndromes 
(TRILOGY ACS) trial compared the efficacy and safety 
of prasugrel versus clopidogrel among 7243 patients <75 
years with ACS receiving aspirin and undergoing 
conservative management.48 At a median follow-up of 
17 months, no differences with regard to the primary 
composite endpoint (CV death, non-fatal MI or stroke) 
(13.9% vs 16%, HR 0.91, 95% CI 0.79 to 1.05, p=0.21) and 
severe or intracranial bleeding were observed between 
the two treatment groups.48 The prespecified analysis 
that was performed to account for multiple recurrent 
ischemic events suggested a lower risk in patients <75 
years in the prasugrel group (HR 0.85, 95% CI 0.72 to 
1.00, p=0.04).48 Conversely, in the subgroup analysis of 
the PLATO trial including 5216 patients (28% of the 
total population) managed conservatively, the clinical 
benefit of ticagrelor over clopidogrel was consistent with 
the results in the overall study population, with a 15% 
reduction in the composite primary endpoint (12.0% vs 
14.3%, HR 0.85, 95% CI 0.73 to 1.00, p=0.04) and a 25% 
reduction in all-cause mortality (6.1% vs 8.2%, HR 0.75, 
95% CI 0.61 to 0.93, p=0.01), despite a numerically higher 
incidence of total major bleeding (11.9% vs 10.3%, HR 
1.17, 95% CI 0.98 to 1.39, p=0.08) and nonCABG-related 
major bleeding (4.0% vs 3.1%, HR 1.30, 95% CI 0.95 to 
1.77, p=0.10) with ticagrelor than with clopidogrel.49 
These results confirm the potential clinical superiority 
of an intense platelet inhibition with ticagrelor (but not 
prasugrel) over clopidogrel for selected patients with 
ACS undergoing conservative management.
Current guidelines recommend DAPT combining 
low-dose aspirin (75–100 mg/day) and a P2Y12 receptor 
inhibitor (clopidogrel or ticagrelor) during 12 months 
for patients with ACS managed conservatively (class 
I).5 6 Although the use of ticagrelor over clopidogrel 
seems reasonable (class IIa),6 the administration of pras-
ugrel is not recommended (class III).5 Long-term DAPT 
may be considered for selected patients who tolerated 
the DAPT regimen during the first 12 months without 
bleeding (class IIb)6 (figure 2).
Notwithstanding, contemporary randomised data 
on the optimal DAPT strategy for medically managed 
patients with ACS are scarce. Patients with ACS under-
going conservative management represent a large and 
highly heterogeneous population, and the generalisation 
of recommendations on the duration of DAPT for 
patients with ACS treated with PCI to this specific patient 
subgroup is questionable in view of the currently available 
evidence. Future research to determine the optimal anti-
platelet regimen and duration in conservatively managed 
patients with ACS is therefore warranted.
percutaneous coronary intervention
Intense P2Y12 receptor inhibition for patients with ACS 
undergoing PCI has been shown to improve clinical 
outcomes in RCTs comparing DAPT regimens with clopi-
dogrel versus placebo,50 prasugrel versus clopidogrel,51 
or ticagrelor versus clopidogrel.52
In the subgroup of 2658 patients with NSTE-ACS 
undergoing PCI in the CURE study, pretreatment 
(median 6 days) followed by long-term therapy (median 
10 days) with clopidogrel and aspirin was associated with 
a 31% reduction in the composite endpoint of CV death 
or MI at 30 days (8.8% vs 12.6%, RR 0.69, 95% CI 0.54 
to 0.87, p=0.002) compared with aspirin and placebo.50 
After PCI, most patients (>80%) in both arms (including 
in the aspirin alone arm) received open-label thieno-
pyridine for about 4 weeks, after which study drug was 
restarted for a mean duration of 8 months.50 The Trial 
to Assess Improvement in Therapeutic Outcomes by Optimising 
Platelet Inhibition with Prasugrel–Thrombolysis in Myocar-
dial Infarction (TRITON-TIMI) 38 compared the clinical 
benefits of prasugrel versus clopidogrel for a duration 
of  6–15 months in combination with aspirin among 
13 608 patients with moderate-to-high-risk ACS sched-
uled to undergo PCI.51 As compared with clopidogrel, 
prasugrel significantly reduced the risk of the primary 
composite endpoint (CV death, non-fatal MI or stroke) 
by 19% (9.9% vs 12.1%, HR 0.81, 95% CI 0.73 to 0.90), 
MI by 24% (7.3% vs 9.5%, HR 0.76, 95% CI 0.67 to 
0.85), urgent target-vessel revascularisation (TVR) by 
34% (2.5% vs 3.7%, HR 0.66, 95% CI 0.54 to 0.81) and 
ST by 52% (1.1% vs 2.4%, HR 0.48, 95% CI 0.36 to 0.64) 
at 12 months (p<0.001 for all), but increased the risk 
of nonCABG-related thrombolysis in myocardial infarc-
tion (TIMI) major bleeding (2.4% vs 1.8%, HR 1.32, 
95% CI 1.03 to 1.6, p=0.03), including fatal bleeding.51 
Overall mortality did not differ significantly between 
treatment groups (3.0% vs 3.2%, HR 0.95, 95% CI 0.78 
to 1.16, p=0.64).52 In a posthoc subgroup analysis of 
patients with age ≥75 years, body weight <60 kg or history 
of stroke or transient ischaemic attack (TIA), prasugrel 
was associated with reduced clinical benefit with regard 
to the primary efficacy endpoint (16.1% vs 16.0%, HR 
1.02, 95% CI 0.84 to 1.24, p=0.83) and increased risk of 
nonCABG-related TIMI major bleeding (4.3% vs 3.3%, 
HR 1.42, 95% CI 0.93 to 2.15, p=0.10) when compared 
with the overall cohort, resulting in less net clinical 
benefit or in clinical harm compared with clopidogrel.51
In the PLATO trial, ticagrelor was compared with 
clopidogrel in addition to aspirin in 18 624 patients with 
ACS.52 At 12-month follow-up, ticagrelor significantly 
reduced the risk of the primary composite endpoint (CV 
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death, non-fatal MI or stroke) by 16% (9.8% vs 11.7%, 
HR 0.84, 95% CI 0.77 to 0.92, p<0.001), MI by 16% (5.8% 
vs 6.9%, HR 0.84, 95% CI 0.75 to 0.95, p=0.005), all-cause 
(4.5% vs 5.9%, HR 0.78, 95% CI 0.69 to 0.89, p<0.001) 
and CV mortality (4.0% vs 5.1%, HR 0.79, 95% CI 0.69 to 
0.91, p=0.001) by 22% and 21% respectively, compared 
with clopidogrel.52 Although no significant difference 
was observed in the overall incidence of major bleeding 
(11.6% vs 11.2%, HR 1.04, 95% CI 0.95 to 1.13, p=0.43), 
ticagrelor was associated with significantly increased rates 
of nonCABG-related major bleeding (4.5% vs 3.8%, HR 
1.19, 95% CI 1.02 to 1.38, p=0.03). The significant differ-
ences in TRITON-TIMI 3851 and PLATO52 study designs 
preclude any interpretation from indirect comparisons 
between the two potent oral P2Y12 receptor inhibitors. 
Recently, the efficacy and safety of ticagrelor versus pras-
ugrel in patients with STEMI treated with primary PCI 
were compared in the Comparison of Prasugrel and Ticagrelor 
in the Treatment of Acute Myocardial Infarction (PRAGUE-
18) study, which was prematurely terminated for futility 
after inclusion of 1230 patients.53 The occurrence of the 
primary composite endpoint (death, MI, TVR, stroke, 
serious bleeding requiring transfusion or prolonging 
hospitalisation) at 7 days was not significantly different 
between patients receiving prasugrel and ticagrelor 
(4.0% vs 4.1%, OR 0.98, 95% CI 0.55 to 1.73, p=0.94) and 
no significant difference was found in any of the compo-
nents of the primary composite endpoint.53 The occur-
rence of the secondary composite endpoint (CV death, 
non-fatal MI or stroke) within 30 days was similar among 
patients treated with prasugrel or ticagrelor (2.7% vs 
2.5%, OR 1.06, 95% CI 0.53 to 2.15, p=0.86).53 Despite 
being small and underpowered, this first head-to-head 
comparison of prasugrel and ticagrelor  in patients with 
STEMI undergoing primary PCI does not support the 
superiority of one of the potent P2Y12 receptor inhibitors 
for the prevention of ischaemic and bleeding events.
Current guidelines recommend DAPT combining 
long-term, low-dose aspirin (75–100 mg/day) and a P2Y12 
receptor inhibitor therapy (clopidogrel, ticagrelor or 
prasugrel) for at least 12 months in patients with ACS 
undergoing PCI, irrespective of the stent type (BMS or 
DES) (class I).5 6 The use of potent P2Y12 receptor antag-
onists (ticagrelor for patients at moderate-to-high risk of 
ischaemic events, including patients who were pretreated 
with clopidogrel, or prasugrel) should be preferred over 
clopidogrel (patients who cannot receive ticagrelor or 
prasugrel, or who require long-term OAC therapy).5 6 
Prasugrel is not recommended for patients in whom coro-
nary anatomy is not known (class III),5 or with history of 
Figure 2 P2Y12 receptor inhibitor therapy for secondary prevention of patients with acute coronary syndrome. BMS, bare 
metal stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; PCI, 
percutaneous coronary intervention.
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stroke or TIA (class III).5 6 In patients at high bleeding 
risk or who develop significant bleeding, premature 
discontinuation of DAPT after 35 or 65 6 months may 
be reasonable (class IIb). In patients with low bleeding 
risk who have tolerated DAPT during 12 months without 
bleeding complications, long-term continuation of DAPT 
may be considered (class IIb)6 (figure 2).
Nevertheless, current recommendations on the optimal 
duration of DAPT in patients with ACS are not based on 
contemporary randomised evidence.50–52 Notably, the 
median duration of DAPT in the pivotal trials evaluating 
the efficacy and safety of the combination of aspirin and 
a P2Y12 receptor inhibitor in patients with ACS was 9–12 
months with clopidogrel,50 14.5 months with prasugrel51 
and only 9.2 months with ticagrelor.52 Furthermore, no 
randomised evidence focused on patients with ACS is 
currently available comparing shorter versus standard 
or extended DAPT durations with respect to clinical 
outcomes in contemporary practice, whereas randomised 
data from prespecified ACS subgroup analyses of recent 
trials including patients treated with newer generation 
DES have consistently shown that shorter durations of 
DAPT (3–6 months) were non-inferior to 1218 19 22–24 54 55 
or 2420 months with respect to composite endpoints of 
CV events or CV events plus major bleeding. The optimal 
duration of DAPT in patients with ACS treated with 
DES remains therefore still under debate. Large-scale 
randomised trials (REDUCE (NCT02118870), SMART-
DATE (NCT01701453)) are currently investigating 
the efficacy and safety of a short-term DAPT strategy 
(3 months and 6 months, respectively) compared 
with the recommended 12-month DAPT duration in 
patients with ACS undergoing PCI with newer gener-
ation DES and should provide novel insights into this 
important clinical dilemma during the next years.
cAbg surgery
There is little evidence concerning the benefits and 
risks of a combined aspirin and P2Y12 receptor inhib-
itor therapy for patients with ACS undergoing surgical 
revascularisation owing to major concerns concerning 
the risk of perioperative major bleeding complications 
with intense antiplatelet inhibition. In the subgroup of 
patients undergoing CABG in the CURE study (n=2072, 
16.5%), clopidogrel in addition to aspirin was associated 
with a 11% relative risk reduction in rates of the primary 
composite endpoint (CV death, MI or stroke) compared 
with placebo (14.5% vs 16.2%, RR 0.89, 95% CI 0.71 to 
1.11), despite marginally increased rates of life-threat-
ening bleeding events in the clopidogrel arm (5.6% vs 
4.2%, RR 1.30, 95% CI 0.91 to 1.95).55 These findings 
were consistent with the treatment effect observed in 
the overall study population and suggest that the bene-
fits of a DAPT with clopidogrel in patients with ACS may 
outweigh the risks among patients who undergo CABG 
during the initial hospitalisation. Data concerning more 
potent P2Y12 receptor antagonists, prasugrel or ticagrelor, 
are currently limited to posthoc analyses of RCTs. In a 
subgroup analysis of patients with ACS who underwent 
isolated CABG in the TRITON-TIMI 38 study (n=346), 
all-cause mortality within 30 days was significantly 
reduced with prasugrel compared with clopidogrel (2.3% 
vs 8.7%, OR 0.26, p=0.025), despite significantly higher 
mean chest tube blood loss at 12 hours and platelet trans-
fusion rates, and marginally increased rates of red blood 
cell transfusion and surgical re-exploration for bleeding 
in the prasugrel arm.56 In the subgroup of patients with 
ACS who underwent CABG within 7 days after the last 
study drug intake in the PLATO trial (n=1261, 6.8%), 
ticagrelor was associated with significantly reduced rates 
of total mortality (4.7% vs 9.7%, HR 0.49, 95% CI 0.32 
to 0.77, p<0.01) and CV death (4.1% vs 7.9%, HR 0.52, 
95% CI 0.32 to 0.85, p<0.01) compared with clopidogrel.57 
The relative risk reduction of the primary composite 
endpoint (CV death, MI or stroke) at 12 months in the 
CABG subgroup (10.6% with ticagrelor vs 13.1% with 
clopidogrel, HR 0.84, 95% CI 0.60 to 1.16, p=0.29) was 
consistent with the results of the overall trial, without 
significant difference in CABG-related major bleeding 
rates between treatment arms.57
For patients with ACS (NSTE-ACS or STEMI) treated 
with DAPT and undergoing surgical revascularisation, 
current guidelines recommend to resume the P2Y12 
receptor inhibitor therapy after CABG to complete 
the 12-month DAPT duration after ACS (class I)3 5 6 
(figure 2). Due to the lack of randomised evidence, the 
appropriate antiplatelet regimen after CABG remains an 
area of controversy, and large, multicentre, randomised 
clinical trials are needed to definitively investigate the 
role of DAPT in patients with ACS after CABG.
specIAl populAtIons And condItIons
High-risk patients with prior acute mI
Current guidelines recommend DAPT with a P2Y12 
receptor antagonist for 1 year after acute MI.3 5 6 
However, patients with prior MI remain at increased 
long-term risk for ischaemic events (CV death, MI or 
stroke) during the subsequent years.58 The potential 
benefit of extended duration of DAPT beyond 1 year 
for the long-term secondary prevention of CV events 
after MI remains a matter of debate. In a posthoc anal-
ysis of the CHARISMA trial, high-risk patients with 
documented prior MI, ischaemic stroke or symptomatic 
PAD (n=9478) were shown to derive significant benefit 
with regard to subsequent ischaemic events from long-
term intensification of antiplatelet therapy beyond 
aspirin alone. After a median follow-up duration of 
27.6 months, rates of the primary composite endpoint 
(CV death, MI or stroke) were significantly lower in the 
DAPT arm combining aspirin and clopidogrel than in 
the aspirin arm (7.3% vs 8.8%, HR 0.83, 95% CI 0.72 to 
0.96, p=0.01) without significant differences in severe 
bleeding rates (1.7% vs 1.5%, HR 1.12, 95% CI 0.81 
to 1.53, p=0.50). However, the incidence of moderate 
bleeding was significantly increased in the aspirin plus 
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clopidogrel group (2.0% vs 1.3%, HR 1.60, 95% CI 1.16 
to 2.20, p=0.004).
The Prevention of Cardiovascular Events in Patients with 
Prior Heart Attack Using Ticagrelor Compared with Placebo on 
a Background of Aspirin-Thrombolysis in Myocardial Infarction 
54 (PEGASUS-TIMI 54) trial is the largest RCT to date 
evaluating the benefits of long-term DAPT for secondary 
prevention in high-risk patients with prior MI. PEGA-
SUS-TIMI 54 randomised 21 162 patients with stable 
CAD, prior MI 1–3 years before inclusion and at high CV 
risk (≥1 high risk criteria: age ≥65 years, diabetes, second 
MI, multivessel CAD or chronic kidney disease) to aspirin 
monotherapy (75–150 mg daily) versus DAPT combining 
aspirin and ticagrelor (60 or 90 mg twice daily).59 After a 
median follow-up of 33 months, the two ticagrelor doses 
in addition to aspirin were associated with significantly 
reduced rates of the primary composite efficacy endpoint 
(CV death, MI or stroke) as compared with placebo 
(7.85%, 7.77% and 9.04% at 3 years in ticagrelor 90 mg 
twice daily, ticagrelor 60 mg twice daily and placebo 
groups, respectively; HR ticagrelor 90 mg vs placebo 
0.85, 95% CI 0.75 to 0.96, p=0.008; HR ticagrelor 60 mg 
vs placebo 0.84, 95% CI 0.74 to 0.95, p=0.004).59 Rates of 
TIMI major bleeding were higher with ticagrelor than 
with placebo (2.6%, 2.3% and 1.06% at 3 years, respec-
tively; HR ticagrelor 90 mg vs placebo 2.69, 95% CI 1.96 to 
3.70, p<0.001; HR ticagrelor 60 mg vs placebo 2.32, 95% CI 
1.68 to 3.21, p<0.001), whereas rates of fatal bleeding or 
non-fatal intracranial haemorrhage did not differ signifi-
cantly between either ticagrelor dose group and placebo 
(0.63%, 0.71% and 0.6% at 3 years, respectively).59 These 
findings were recently confirmed in a large meta-analysis 
including 33 435 high-risk patients with history of MI.60 
After a mean follow-up of 31 months, prolonged DAPT 
was associated with significantly reduced rates of MACE 
(6.4 vs 7.5%, RR 0.78, 95% CI 0.67 to 0.90, p=0.001), 
CV death (2.3 vs 2.6%, RR 0.85, 95% CI 0.74 to 0.98, 
p=0.03), MI (RR 0.70, 95% CI 0.55 to 0.88, p=0.003), 
stroke (RR 0.81, 95% CI 0.68 to 0.97, p=0.02) and ST (RR 
0.50, 95% CI 0.28 to 0.89, p=0.02), when compared with 
aspirin alone, with no significant increase in non-CV (RR 
1.03, 95% CI 0.86 to 1.23, p=0.76) and all-cause mortality 
(RR 0.92, 95% CI 0.83 to 1.03, p=0.13).60 Extended DAPT 
was associated with increased risk of major bleeding (1.85 
vs 1.09%, RR 1.73, 95% CI 1.19 to 2.50, p=0.004) but not 
fatal bleeding (0.14 vs 0.17%, RR 0.91, 95% CI 0.53 to 
1.58, p=0.75).60
In a posthoc analysis of PEGASUS-TIMI 54, the net clin-
ical benefit of ticagrelor for long-term secondary preven-
tion in high-risk patients with prior MI seemed more 
pronounced in patients continuing on, or restarting 
after only a brief interruption, P2Y12 inhibition, when 
compared with patients with stable CAD (no MACE for >2 
years after MI) and off P2Y12 inhibitor therapy for >1 year, 
irrespective of time from MI.61 For clinicians considering 
a strategy of prolonged DAPT in high-risk patients post-
MI, these data suggest greater benefit in the continuation 
of P2Y12 inhibitor therapy without interruption after MI, 
rather than reinitiating such therapy in patients who have 
remained stable for an extended period.
In patients at high ischaemic risk after acute MI, contin-
uation of P2Y12 receptor inhibitor therapy (preferably 
with ticagrelor 60 mg twice daily) in addition to low-dose 
aspirin beyond 1 year may be considered after careful 
assessment of the patient ischaemic and bleeding risks 
(class IIb) (figures 1 and 2).5 6 However, future studies 
and development of practical clinical tools are warranted 
to clarify further the optimal selection of post-MI patients 
most likely to derive clinical benefit from long-term 
DAPT after MI.
patients requiring long-term oral anticoagulant therapy
Approximately 6–8% of patients undergoing PCI have 
a concomitant indication for long-term OAC with a 
vitamin K antagonist (VKA) or a non-VKA oral antico-
agulant (NOAC) for conditions such as atrial fibrillation 
(AF), left ventricular thrombus, mechanical valve pros-
thesis or venous thromboembolism. Current evidence 
to guide the management of patients undergoing PCI 
and requiring long-term OAC practice remains limited. 
Compared with VKA alone, dual therapy (clopidogrel 
and VKA) and triple therapy (VKA and DAPT with a 
P2Y12 receptor inhibitor) in patients with AF following MI 
or PCI have been shown to increase the risk of major fatal 
and non-fatal bleeding.62 Omission of aspirin while main-
taining P2Y12 receptor antagonist has been evaluated in 
the What is the Optimal antiplatElet and anticoagulant therapy 
in patients with OAC and coronary StenTing (WOEST) trial, 
an open-label, multicentre RCT including 573 patients 
receiving oral anticoagulant therapy (AF or flutter 69%) 
and candidates for PCI (DES 65%) for stable CAD or 
ACS (25%–30%), who were assigned to clopidogrel alone 
(dual therapy) or clopidogrel plus aspirin (triple therapy) 
for 1 month after BMS and 1 year after DES.63 The rates 
of the primary safety outcome (any bleeding episode) at 
1 year were significantly reduced in the dual therapy arm, 
as compared with the triple therapy arm (19.4% vs 44.4%, 
HR 0.36, 95% CI 0.26 to 0.50, p<0.0001), mainly driven 
by significant reductions in non-intracranial bleedings.63 
Despite being small and underpowered for hard clinical 
outcomes, the trial showed a significant reduction of the 
secondary composite ischaemic endpoint (death, MI, 
stroke, TVR or ST) in the dual therapy group (11.1% 
vs 17.6%, HR 0.60, 95% CI 0.38 to 0.94, p=0.025) as 
compared with patients on triple therapy.63 These data 
suggest the potential superiority of dual antithrombotic 
therapy with regard to occurrence of major bleedings 
compared with triple therapy among patients under-
going PCI and who are candidates for long-term OAC, 
without evidence of increased risk of thrombotic events 
by omission of aspirin.
The Intracoronary Stenting and Antithrombotic Regi-
men-Testing of a 6 Week Versus a 6 Month Clopidogrel Treat-
ment Regimen in Patients With Concomitant Aspirin and 
Oral Anticoagulant Therapy Following Drug-Eluting Stenting 
(ISAR-TRIPLE) trial enrolled 614 patients receiving OAC 
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and who underwent DES implantation to 6-week versus 
6-month clopidogrel therapy in addition to aspirin.64 
The rates of the primary composite endpoint (death, MI, 
definite ST, stroke or TIMI major bleeding) at 9 months 
were similar between the two treatment groups (9.8% vs 
8.8%, HR 1.14, 95% CI 0.68 to 1.91, p=0.63).64 Despite 
low event rates, there were no significant differences for 
the secondary combined ischaemic endpoint (CV death, 
MI, definite ST and ischaemic stroke) (4.0% vs 4.3%, 
HR 0.93, 95% CI 0.43 to 2.05, p=0.87) or the secondary 
bleeding endpoint of TIMI major bleeding (5.3% vs 
4.0%, HR 1.35, 95% CI 0.64 to 2.84, p=0.44).64
Recently, the Open-Label, Randomised, Controlled, Multi-
center Study Exploring Two Treatment Strategies of Rivaroxaban 
and a Dose-Adjusted Oral Vitamin K Antagonist Treatment 
Strategy in Subjects with Atrial Fibrillation who Undergo Percu-
taneous Coronary Intervention (PIONEER AF-PCI) trial 
randomly assigned 2124 patients with non-valvular AF 
who underwent PCI to receive in a 1:1:1 ratio low-dose 
rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 
12 months (group 1), very-low-dose rivaroxaban (2.5 mg 
Figure 3 Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary 
intervention. ACS: acute coronary syndrome; NOAC: non-vitamin K antagonist oral anticoagulant; PCI: percutaneous coronary 
intervention; OAC: oral anticoagulation; SCAD: stable coronary artery disease; VKA: vitamin K antagonist. aDual therapy with 
oral anticoagulation and single antiplatelet therapy (aspirin or clopidogrel) may be considered in selected patients at low 
ischaemic risk. bDual antiplatelet therapy (aspirin and clopidogrel) may be considered. cDual therapy with oral anticoagulation 
and aspirin (as an alternative to clopidogrel) may be considered. dDual therapy with oral anticoagulation and single antiplatelet 
therapy (aspirin or clopidogrel) up to 12 months may be considered in selected patients, particularly for patients managed 
medically or undergoing CABG. eDual therapy with oral anticoagulation and a single antiplatelet agent (aspirin or clopidogrel) 
may be considered in patients at very high risk of coronary events. fDual therapy with oral anticoagulation and clopidogrel may 
be considered in selected patients at low ischaemic risk. gTriple therapy with oral anticoagulation and dual antiplatelet therapy 
(aspirin and clopidogrel) may be considered up to 12 months in very selected patients at high risk of ischaemic events: prior 
stent thrombosis on adequate antiplatelet therapy, left main coronary artery or last remaining patent coronary artery stenting, 
multiple stenting in proximal coronary artery segments, two stents bifurcation treatment, or diffuse multivessel coronary artery 
disease, particularly in patients with diabetes mellitus. hChoice and dose of oral anticoagulants used in combination with 
antiplatelet therapy: Vitamin K antagonist (International Normalised Ratio 2-2,5); Dabigatran 110 mg once daily; Rivaroxaban 15 
mg once daily; Apixaban 2,5 mg twice daily; Edoxaban 30 mg (or 15 mg) once daily.
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twice daily) plus DAPT for 1, 6 or 12 months (group 2), or 
standard therapy with a dose-adjusted VKA plus DAPT for 
1, 6 or 12 months (group 3).65 At 12 months, rates of the 
primary safety endpoint (clinically significant bleeding) 
were significantly lower in the two groups receiving 
rivaroxaban compared with the standard therapy group 
(16.8% in group 1, 18.0% in group 2 and 26.7% in group 
3; HR for group 1 vs group 3 0.59, 95% CI 0.47 to 0.76, 
p<0.001; HR for group 2 vs group 3 0.63, 95% CI 0.50 
to 0.80, p<0.001).65 The secondary combined ischaemic 
endpoint (CV death, MI or stroke) occurred similarly in 
the three treatment groups (6.5% in group 1, 5.6% in 
group 2 and 6.0% in group 3; p values for all comparisons 
non-significant).65 Notwithstanding, the absence of a 
‘WOEST-like’ control arm and the broad CIs observed for 
individual components of the secondary endpoint may 
preclude any definitive conclusions concerning the risk 
of thrombotic events of a low-dose or very low-dose rivar-
oxaban strategy combined with P2Y12 inhibitor mono-
therapy or DAPT. Future randomised studies adequately 
powered for efficacy endpoints are needed to confirm 
the potential superiority of an antithrombotic strategy 
combining a low-dose NOAC and a P2Y12 receptor inhib-
itor monotherapy over triple antithrombotic therapy for 
patients with non-valvular AF undergoing PCI.
Until further data from large RCTs become available, 
current consensus statements recommend an individual-
ised approach and advocate to limit as possible the duration 
of triple therapy, depending on the clinical setting (stable 
CAD vs ACS), the thromboembolic risk (CHA2DS2-VASc 
score) and the bleeding risk (eg, HAS-BLED score)6 66 
(figure 3). The indication for OAC should be carefully 
reassessed in patients requiring DAPT and anticoagu-
lant therapy continued only if a compelling indication is 
Figure 4 P2Y12 receptor inhibitor therapy for secondary prevention of patients with coronary artery disease. BMS, bare metal 
stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MI, myocardial 
infarction; PCI, percutaneous coronary intervention.
15Degrauwe S, et al. Open Heart 2017;4:e000651. doi:10.1136/openhrt-2017-000651
Interventional cardiology
present. The dose intensity of OAC should be carefully 
monitored with a target INR of 2.0–2.5 in patients treated 
with VKA (except patients with mitral mechanical pros-
thetic valves) and time in therapeutic window of >70%. In 
patients treated with an NOAC, the lowest dose evaluated 
for stroke prevention should be used. In the absence of 
randomised evidence with respect to safety and efficacy, 
the use of prasugrel or ticagrelor as part of triple therapy 
should currently be avoided.5 66 Nevertheless, the optimal 
management strategy of patients undergoing PCI and 
requiring long-term OAC represents an unmet clinical 
need in contemporary practice. Future research focused 
on this high-risk patient population and adequately 
designed and powered to determine the antithrombotic 
regimen and duration that provides the optimal balance 
between efficacy and safety is warranted.
conclusIon
Despite a large body of randomized evidence, the optimal 
regimen and duration of DAPT for secondary prevention 
of patients with CAD remains a matter of intense debate. 
Future studies are needed to better identify patients who 
may derive benefit from either shortened or prolonged 
DAPT durations to improve outcomes while minimising 
bleeding risks. Until more evidence becomes available, 
the optimal DAPT regimen and duration for patients 
with CAD requires a tailored approach based on the 
patient clinical presentation, baseline risk profile and 
management strategy (figure 4). Several ongoing large-
scale randomised trials are currently investigating novel 
antiplatelet strategies and will contribute to refining the 
optimal regimen and duration of DAPT for secondary 
prevention of patients with CAD in the near future.
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